Login to Your Account

Wilson Therapeutics AB raised $40 million in a series B round to fund clinical development of WTX101 in Wilson's disease, a genetic disorder characterized by pathological accumulations of copper.
Cell therapy developer Txcell SA grossed just €16.2 million (US$22.4 million) in a scaled-back initial public offering (IPO) on the Euronext exchange in Paris, evidence that Europe's big funding freeze may be thawing but only gradually.
Tigenix NV has thrown in the towel on its efforts to obtain broad reimbursement in Europe for its Chondrocelect autologous cell therapy for regenerating cartilage in the knee and has signed over marketing and distribution rights to Swedish Orphan Biovitrum AB (Sobi) in return for double-digit sales royalties.
More EUROPE Headlines

Cast Your Vote

Has biotech’s bubble burst?: